Heart failure & cardiomyopathies

Avoiding Treatment in Hospital With Subcutaneous Furosemide for Worsening Heart Failure: A Pilot Study (AT HOME-HF)

JACC Heart FailPublished Randomised controlled trial

Primary result · Win ratio (CV death, HF events, NT-proBNP change)Result — go to the resultWin ratio 1.11 95% CI 0.48–2.50

Authors' conclusion

SC furosemide augmented weight loss in patients with HF and worsening congestion. The composite primary endpoint was not statistically significant in this pilot investigation.

Study context

Population
Outpatients with chronic heart failure (HF) and worsening congestion
Participants
34 vs 17
Comparison
Subcutaneous (SC) furosemide vs usual care
  • SC furosemiden = 34
  • Usual care (UC)n = 17reference
Primary endpoint
Win ratio of hierarchical composite of:
  • CV death
  • HF events
  • Change in NT-proBNP
Follow-up
30 days
Methodological detailsopen-label, pilot, 2:1 randomisation
  • Open-label
  • Pilot
  • 2:1 randomisation

Primary result

As reported in the abstract

Win ratio (CV death, HF events, NT-proBNP change)

Win ratio

1.11

95% CI 0.48–2.50

P = 0.806

SC furosemide vs UC
win ratio 1.11 (95% CI 0.48–2.50); P = 0.806

Secondary outcomes

OutcomeDifference in least square mean change (kg) (95% CI)P value
Body weight change · day 3−2.02 (−3.9 to −0.14)P = 0.035
OutcomeLeast square mean difference (95% CI)P value
KCCQ-12 Overall Summary Score · trend9.15 (1.95–20.3)P = 0.106
OutcomeEstimateP value
7-point dyspnea score · favoring SC furosemideP = 0.017
6-minute walk test · favoring SC furosemideP = 0.032

Safety

OutcomeSC furosemideUC
Most common related AE: mild infusion site pain11.8%Not reported in the abstractUC: not reported in the abstract

Original publication

Avoiding Treatment in Hospital With Subcutaneous Furosemide for Worsening Heart Failure: A Pilot Study (AT HOME-HF). JACC Heart Fail. Published 11 September 2024. doi:10.1016/j.jchf.2024.07.015

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.